10-QPeriod: Q1 FY2023

Medtronic plc Quarterly Report for Q1 Ended Jul 29, 2022

Filed September 1, 2022For Securities:MDT

Summary

Medtronic plc's Q2 Fiscal Year 2023 results, filed August 31, 2022, show a decrease in net sales to $7,371 million from $7,987 million in the prior year's comparable period, an 8% decline. This was primarily attributed to ongoing supply chain challenges and the lingering effects of the COVID-19 pandemic impacting procedure volumes. Diluted earnings per share (EPS) also saw a decrease, with GAAP EPS at $0.70 compared to $0.56 in the prior year. However, on a non-GAAP basis, adjusted diluted EPS was $1.13, an improvement from $1.36 in the prior year when excluding significant one-time charges such as MCS impairment and restructuring costs. The company reported a strategic acquisition of Intersect ENT for $1.2 billion, bolstering its Neuroscience segment, and announced the subsequent acquisition of Affera, Inc. Despite revenue headwinds, Medtronic continued to invest in innovation and returned capital to shareholders through share repurchases and dividends. The company's strong balance sheet and liquidity position remain robust, providing flexibility for future operations and strategic initiatives.

Financial Highlights

54 data points
Beta

Revenue

$7.37B

65.9% Gross Margin

Net Income

$931.00M

12.6% Net Margin

EPS (Diluted)

$0.70

Total Assets

$89.91B

Cash & Equivalents

$2.14B

Free Cash Flow

$657.00M

Financial Statements
Beta
Revenue$7.37B
Cost of Revenue$2.52B
Gross Profit$4.86B
SG&A Expenses$2.57B
Operating Income$1.13B
Interest Expense$164.00M
Net Income$931.00M
EPS (Basic)$0.70
EPS (Diluted)$0.70
Shares Outstanding (Basic)1.33B
Shares Outstanding (Diluted)1.33B

Key Highlights

  • 1Net sales decreased by 8% to $7.37 billion, impacted by supply chain issues and the pandemic.
  • 2GAAP diluted EPS was $0.70, down from $0.56 in the prior year.
  • 3Non-GAAP adjusted diluted EPS was $1.13, showing resilience when excluding certain charges.
  • 4Acquired Intersect ENT for $1.2 billion to strengthen the Neuroscience segment.
  • 5Free Cash Flow was $657 million, a decrease from $914 million in the prior year, largely due to increased acquisitions.
  • 6The company reported a goodwill impairment of $61 million related to the planned divestiture of half of its Renal Care Solutions (RCS) business.
  • 7Medtronic continued its share repurchase program, with approximately $2.6 billion remaining under the authorized program.

Frequently Asked Questions

The primary drivers of the revenue decline were persistent supply chain disruptions, particularly impacting certain businesses, and the ongoing effects of the COVID-19 pandemic on global medical procedure volumes. Additionally, specific segments like Medical Surgical and Cardiovascular experienced declines due to factors such as lockdowns in China, provincial tender pricing, and challenges in specific product lines like ventilators and coronary/peripheral vascular products.

While GAAP net sales decreased, Medtronic's profitability showed resilience when viewed on a non-GAAP basis. GAAP diluted EPS was $0.70, down from $0.56 in the prior year. However, when excluding significant one-time charges and adjustments, such as restructuring costs, acquisition-related items, and impairments, the non-GAAP adjusted diluted EPS was $1.13. This indicates that the core operational profitability, excluding these specific items, remained strong.

Medtronic made a significant strategic acquisition of Intersect ENT for $1.2 billion, which is expected to expand its Neuroscience segment portfolio. Furthermore, the company announced the subsequent acquisition of Affera, Inc., a developer of cardiac mapping and ablation technologies, aimed at enhancing its Cardiovascular segment. The company also advanced its plan to divest half of its Renal Care Solutions (RCS) business through an agreement with DaVita Inc.

Medtronic acknowledges that supply chain disruptions and macroeconomic factors, including inflation, rising interest rates, and geopolitical events like the Russia-Ukraine conflict, continue to pose risks. The company expects these challenges to persist and potentially impact future results. However, they are actively managing these challenges through supplier relationships and operational improvements. The company is also monitoring the uneven impact of COVID-19 on procedure volumes and healthcare system staffing.